HUTCHMED (China) (HCM) Corporate presentation summary

Financial performance and outlook

• H1 2026 in-market sales $280m, up 19% YoY; FRUZAQLA $185m (+14%), ELUNATE $61m (+41%), SULANDA $18m (+45%) and ORPATHYS and others $16m (+3%).

• Consolidated revenue $278m, unchanged YoY; Oncology/Immunology revenue $162m (+13%), other oncology revenue $41m (-8%) and other ventures revenue $116m (-14%).

• FY2026 Oncology/Immunology consolidated revenue guidance reiterated at $330m-$450m.

• H1 R&D expenses $79m vs. $72m in H1 2025; net income $16m vs. $455m, including a prior-period $416m SHPL divestment gain and $21m share of SHPL profits before divestment; cash ~ $1.4bn.

Global licensing agreement

• Global rights to HMPL-A830, a KRAS-EGFR ATTC, licensed to GSK ex-China; total potential deal value up to $1.295bn, including $110m upfront and potential milestones, plus tiered royalties.

• Full development and commercialization rights retained in Mainland China, Hong Kong, Macau and Taiwan; global Phase I led by HUTCHMED, with GSK responsible for subsequent clinical development and commercialization in its territory.

• The agreement is intended to accelerate global development, validate ATTC platform potential and expand oncology reach.

Pipeline and clinical progress

• Savolitinib SAFFRON showed ~4.9 months OS improvement and 32% lower risk of death vs. standard of care; US FDA filing submitted, with EU and Japan filings underway.

• Savolitinib SANOVO reported 11.1 months PFS extension and 52% lower risk of death in OS vs. osimertinib alone in 1L MET-overexpressed EGFR-mutated NSCLC.

• HMPL-A251, HMPL-A580 and HMPL-A830 are in global Phase I; multiple earlier-stage assets are entering preclinical studies through an AI-aided discovery platform.

• Sovleplenib NDA approvals expected H1 2027 for ITP and mid-2027 for WAIHA; ESLIM-01 and ESLIM-02 showed durable response rates of 48.4% and 66%, respectively, vs. 0% and 15% for placebo.

• HMPL-760 Phase III in r/r DLBCL targets 240 patients, with enrollment completion targeted for H2 2027; Phase II enrolled 61 patients.